European Position Paper On Rhinosinusitis And Nasal Polyps (EP3OS) Group Updates 2005 Guidelines
Main Category: Ear, Nose and ThroatAlso Included In: Allergy; Dermatology
Article Date: 14 Jun 2007 - 1:00 PDT
| Patient / Public: | ![]() |
3 (1 votes) |
| Healthcare Prof: | ![]() |
4.4 (5 votes) |
The European Position Paper on Rhinosinusitis and Nasal Polyps (EP3OS) group, a task force of the European Academy of Allergology and Clinical Immunology (EAACI), has issued updated guidance on the treatment of acute and chronic rhinosinusitis and nasal polyposis. Rhinosinusitis, which can cause severe congestion and a runny nose, is a significant and increasing health problem which results in a large financial burden on society. The new guidelines offer the most comprehensive evidence-based recommendations on the diagnosis and management of rhinosinusitis and nasal polyposis for primary care physicians, specialists on ear, nose and throat (ENT), and non-ENT specialists.
Developed by a broad of group of both primary care physicians and specialists to update the knowledge of acute and chronic rhinosinusitis and nasal polyposis, the EP3OS guidelines include a review of diagnostic methods and treatments, propose a step-wise approach to the management of the disease, explore new findings on how rhinosinusitis develops and consider how we can make progress with continued research in this area. The complete guidelines are published in a special supplement of this month's issue of the journal Rhinology.
"The EP3OS position paper is important because it provides an evidence-based approach to best ensure that patients' symptoms are properly diagnosed and effectively treated," said Prof. Wytske Fokkens, EP3OS Chair. "Because rhinosinusitis is diagnosed by a variety of physicians, it's important to have an accurate, efficient, and accessible definition of the disease that can be applied in numerous situations."
Among the updated information in the guidelines is a new definition of rhinosinusitis aimed at helping physicians better identify and diagnose the disease. EP3OS defines rhinosinusitis (including nasal polyps) as the inflammation of the nose and the paranasal sinuses characterised by two or more symptoms, one of which should be either nasal congestion or nasal discharge. Other symptoms of rhinosinusitis may include facial pain or pressure, reduction or loss of smell; and either endoscopic signs of nasal polyps or mucus and puss discharged primarily from the sinuses, or CT changes showing mucosal changes within the sinuses. Rhinosinusitis symptoms are diagnosed as mild, moderate or severe, depending on symptom severity; and acute or chronic, depending on symptom duration. Individuals with symptoms present less than 12 weeks, with complete symptom resolution, are classified as having acute rhinosinusitis (ARS). Patients with symptoms present more than 12 weeks, without complete resolution of symptoms and subject to symptom exacerbations, are classified as having chronic rhinosinusitis (CRS).
"We've taken a look at a multitude of treatments for the disease and highlighted the level of evidence to support their efficacy in treating rhinosinusitis and nasal polyps," said Dr. Fokkens. "Because there is a substantial amount of new evidence, there are considerable changes in the schemes for diagnosis and treatment."
Updates for ENT specialists are also included in the new guidelines. For ENT specialists, diagnosis of ARS is recommended beyond presence of symptoms for ARS. EP3OS recommends a nasal examination (swelling, redness, pus), oral examination (posterior discharge) and nose and throat examination including nasal endoscopy. Diagnosis of CRS includes nasal endoscopy to determine whether there are visible nasal polyps, as well as a review of the primary care physician's diagnosis and treatment and allergy questionnaire. Appropriate medical treatment is as effective as surgery for the majority of CRS patients, so sinus surgery should be reserved for patients who do not satisfactorily respond to recommended medical treatment. In CRS without polyps additional long-term antibiotics may be of benefit whereas when polyps are present the use of topical steroid (sprays or drops) and oral steroids are stratified according to polyp size.
The new EP3OS report also includes an expanded section on the treatment of rhinosinusitis in children, stratifies the severity of disease based on a visual analogue score, and provides new information on the pathogenesis of rhinosinusitis and the relationship between the upper and lower respiratory tracts.
About EP3OS
EP3OS was first initiated by EAACI and approved by the European Rhinologic Society (ERS) and is intended for the ENT and non-ENT specialists as well as for the general practitioners. It was instigated in 2002 under the chairmanship of Prof WJ Fokkens and Prof VJ Lund, culminating in the first report in 2005.
About EAACI
The European Academy of Allergology and Clinical Immunology (EAACI) is an association including 39 European National Societies, more than 3,500 academicians, research investigators and clinicians aimed at:
-- promoting basic and clinical research
-- collecting, assessing and disseminating scientific information
-- functioning as a scientific reference body for other scientific, health and political organizations
-- encouraging and providing training and continuous education
-- promoting good patient care in this important area of medicine
http://www.eaaci.net
References:
1. EP3OS document. Rhinology 2007, Supplement 20;http://www.rhinologyjournal.com ; http://www.eaaci.net.
2. EP3OS document. Rhinology 2005, Supplement 18 (pp 1-88).
Visit our ear, nose and throat section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/74049.php>
APA
http://www.medicalnewstoday.com/releases/74049.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




